Visus Therapeutics is developing BRIMOCHOL™, a combination of carbachol and brimonidine tartrate eye drops, to treat presbyopia, a condition that causes the loss of near vision. The company aims to provide a best-in-class ophthalmic therapy that enhances patients' ability to see clearly at close distances.
Funding
Funding not disclosed
Founders
Product
Problem
Presbyopia, the age-related loss of near vision, affects a significant portion of the adult population, reducing their ability to focus on close-up objects. Current treatments often involve reading glasses or surgical procedures, which may not be ideal for all patients. There is a need for a non-surgical, pharmacological solution that can improve near vision without significant side effects.
Solution
Visus Therapeutics is developing BRIMOCHOL™, a combination eye drop containing carbachol and brimonidine tartrate, designed to treat presbyopia. BRIMOCHOL™ aims to provide a convenient and effective method for improving near vision by constricting the pupil and reducing peripheral light scatter. The formulation is intended to enhance patients' ability to see clearly at close distances, potentially reducing or eliminating the need for reading glasses. The company has completed Phase 3 clinical trials, demonstrating positive topline data for the efficacy and safety of BRIMOCHOL™ in treating presbyopia.
Target Audience
The primary target audience includes adults experiencing presbyopia who are seeking a non-surgical, pharmacological treatment option to improve their near vision.
Features
- Combination formulation of carbachol and brimonidine tartrate
- Preservative-free (PF) option available (BRIMOCHOL PF™)
- Designed for topical ophthalmic administration
- Demonstrated statistically significant improvement in near visual acuity in Phase 3 clinical trials
- Intended for daily use to manage presbyopia symptoms